



Vivimed

Date: 09.08.2019

To
BSE Limited
P.J.Towers, Dalal Street,
Mumbai – 400001
BSE - Code : 532660

National Stock Exchange of India Ltd.
Exchange Plaza, Plot no. C/1, G Block,
Bandra-Kurla Complex, Bandra (E)
Mumbai - 400 051
NSE- Symbol: VIVIMEDLAB

Dear Sir/Madam

Sub: Outcome of the Meeting of the Board of Directors of the Company – reg.

The Board of Directors of the Company at its meeting held on August 09, 2019 inter alia, have approved / resolved/ taken note of the following:

1. Pursuant to Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 considered and approved the submission of the Un-audited Financial Results (Standalone & Consolidated) for the Quarter ended June 30, 2019 attached herewith;
2. Auditors's Limited Review Report on the Un-audited Financial Statements of the Company for the quarter ended June 30, 2019.
3. Directors Report for the financial year ended 31.03.2019 together with annexure thereto.
4. Convening of Annual General Meeting (AGM) on 30.09.2019 and Notice of AGM.
5. Fixed Book closure dates from Wednesday, September 25, 2019 to Monday, September 30, 2019 (both days inclusive) for the purpose of AGM.
6. With respect to offer or invitation made earlier (Resolutions passed vide postal ballot notice dated 23.08.2018) to issue upto (a) 40,00,000 (Forty Lakhs only) warrants exercisable as per its terms and conditions ("Non - Promoter Warrants") to Non-Promoter and /or Non-Promoter Group of the Company and (b) 85,00,000 (Eighty Five Lakhs only) warrants exercisable as per its terms and conditions ("Promoter Warrants") on a preferential basis to the members of the Promoter and/or Promoter Group of the Company have been withdrawn by the company. The proposed allottees have withdrawn their consent to apply for warrants due to fall in market price of shares. Hence the Board of Directors of the Company has approved the withdrawal of consent by all the proposed allottees.

You are requested to take note of the above.

Yours faithfully
For VIVIMED LABS LIMITED


SANTOSH VARALWAR
MANAGING DIRECTOR



Vivimed Labs Limited.
CIN: L02411KA1988PLC009465
Registered Office: #78/A, Kolhar Industrial Area,
Bidar, Karnataka - 585 403, India.
T +91 (0) 8482-232045, F +91 (0) 8482-232436
Email: contact@vivimedlabs.com | www.vivimedlabs.com

Corporate Office:
North End, Road No. 2
Banjara Hills, Hyderabad,
Telangana - 500 034, India.
GSTIN: 36AAACV6060A1ZQ
T +91(0) 40-6608-6608, F +91(0) 40-6608-6699

VIVIMED LABS LIMITED
UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER ENDED 30.06.2019

Rs. In Lakhs

Sl. No.	Particulars	Quarter Ended			YEAR ENDED
		30.06.2019	31.03.2019	30.06.2018	31.03.2019
		(Unaudited)	(Audited)	(Unaudited)	(Audited)
	<i>Income From Operations</i>				
1	Revenue from operations	34,420.68	34,807.56	35,854.14	1,31,517.03
	Total revenue from operations	34,420.68	34,807.56	35,854.14	1,31,517.03
2	Other Income	126.61	610.18	574.72	2,296.00
3	Total Revenue (1+2)	34,547.29	35,417.75	36,428.86	1,33,813.03
4	Expenses				
a	Cost of material consumed	14,160.16	16,088.15	15,025.35	56,191.14
b	Purchases of Stock- in- Trade				-
c	Changes in inventories of finished goods work in progress and stock-in-Trade	1,678.35	(2,407.47)	(742.70)	(4,351.28)
d	Employee Benefit Expenses	6,132.38	7,567.85	5,798.53	24,176.00
e	Finance Costs	1,210.77	1,283.21	1,928.00	6,726.22
f	Depreciation and Amortisation Expenses	1,695.12	1,605.26	1,586.73	6,678.97
g	Other Expenses	8,340.03	11,420.62	8,892.53	37,787.43
	Total Expenses	33,216.80	35,557.61	32,488.45	1,27,208.49
5	Profit before tax (3-4)	1,330.49	(139.87)	3,940.41	6,604.54
6	Tax expenses				
	Current Taxes	313.75	(132.40)	1,094.77	780.20
	Deferred Taxes	1.94	(8.82)	-	87.70
	Total tax expenses	315.68	(141.22)	1,094.77	867.90
7	Profit for the period /Year before non-controlling interest (5-6)	1,014.81	1.36	2,845.65	5,736.64
8	Non-controlling interest				
9	Profit for the period/ year (7-8)	1,014.81	1.36	2,845.65	5,736.64
10	Other comprehensive income				
	Items that will not be reclassified to profit or loss, net of tax				
	Items that will be reclassified to profit or loss, net of tax				
	Total other comprehensive income	-	-	-	-
11	Non-controlling interest				
12	Other comprehensive income attributable to shareholders(10+11)				
	Total comprehensive income attributable to:				
	Shareholders of the Company	1,014.81	1.36	2,845.65	5,736.64
	Non-controlling interest	-	-	-	-
	Total Comprehensive income	1,014.81	1.36	2,845.65	5,736.64
13	Paid up Equity Share Capital	1,658.28	1,650.48	1,650.48	1,650.48
14	Other equity				
15	Earnings per Share (before Extraordinary Items) (of Rs2/- each) (not annualised)				
	(a) Basic	1.22	0.002	3.45	6.95
	(b) Diluted	1.19	0.002	3.31	6.67

1. The above Consolidated Unaudited Financial Results for the Quarter ended June 30.06.2019 have been reviewed and recommended by the Audit Committee and approved by the Board of Directors at their meeting held on 09.08.2019

2. Consolidated Financial Statements have been prepared in accordance with Accounting Standard-21 issued by ICAI. Consolidated Results are combined numbers of Vivimed Labs Limited and its direct wholly owned subsidiaries, viz., (i) Finoso Pharma Pvt Limited (ii) Vivimed Speciality chemicals Pvt Ltd and its wholly owned foreign subsidiaries viz(i) Vivimed Labs USA, Inc.,(ii)Vivimed Labs Mauritius Limited (iii) Vivimed Holdings Limited and its Step-down subsidiaries (iv) Vivimed Labs Europe Limited (v) Vivimed Labs UK Limited, (vi) Vivimed Labs Spain, S.L. (vii) Union Quimico Farmaceutica S.A.U., Spain, (viii) Holliday International Limited,UK & (ix) Uquifa Mexico S.A. de C.V.(x) Vivimed Labs (Mascarene) Ltd (xi) Soneas Chemicals Ltd (xii) Soneas Research Ltd and its wholly owned Indian subsidiary (i) UQUIFA India Private Limited.

3. In line with provisions of Ind AS 108 Operating segments, the Company has primarily two segments "speciality chemicals" and "Pharma" and accordingly considered under reportable segments by the Company.

4. Corresponding numbers of previous period / year have been regrouped, wherever necessary.



For VIVIMED LABS LIMITED

(SANTOSH VARALWAR)
MANAGING DIRECTOR

Place : Hyderabad
Date : 09.08.2019

VIVIMED LABS LIMITED

SEGMENT-WISE CONSOLIDATED FINANCIAL RESULTS

Rs. In lakhs

Particulars	3 Months Ended			FY 19
	30.06.2019	31.03.2019	30.06.2018	31.03.2019
	(Unaudited)	(Audited)	(Unaudited)	(Audited)
1. Segment Revenue (net sales/income from each segment should be disclosed under this head)				
a.Speciality Chemicals Business	5,954.93	3,415.81	4,167.55	16,269.77
b.Pharma Business	28,465.75	31,391.75	31,686.59	1,15,247.27
Total	34,420.68	34,807.56	35,854.14	1,31,517.03
Less, Inter Segment Revenue				
Net sales / Income from Operations	34,420.68	34,807.56	35,854.14	1,31,517.03
2.Segment Results (Profit) (+) / Loss (-) before tax and interest from each segment				
a.Speciality Chemicals Business	1,282.52	447.83	1,365.21	4,363.34
b.Pharma Business	1,258.74	656.06	4,503.21	8,967.48
Total	2,541.26	1,103.89	5,868.42	13,330.82
Less: 1.Interest	1,210.77	1,267.65	1,928.00	6,726.22
2.Other Un-allocable Expenditure				
3.Un-allocable Income				
Total Profit Before Tax	1,330.49	(163.76)	3,940.42	6,604.60

Segmental capital employed

As certain assets of the company including manufacturing facilities and treasury assets and liabilities are often deployed interchangeability across segments, it is impractical to allocate these assets and liabilities to each segment. Hence, the details for capital employed have not been disclosed in the above table.

Place : Hyderabad

Date : 09.08.2019



For VIVIMED LABS LIMITED

(SANTOSH VARALWAR)
MANAGING DIRECTOR

VIVIMED LABS LIMITED

UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER ENDED 30.06.2019

Rs in Lakhs

Sl. No.	Particulars	3 Months Ended			Year Ended
		30.06.2019	31.03.2019	30.06.2018	31.03.2019
		(Unaudited)	(Audited)	(Unaudited)	(Audited)
	Income From Operations				
1	Revenue from Operations	5,911.14	7,459.95	6,198.53	25,180.77
	Total revenue from operations	5,911.14	7,459.95	6,198.53	25,180.77
2	Other Income	262.54	764.14	56.39	853.42
3	Total Revenue (1+2)	6,173.68	8,224.09	6,254.92	26,034.19
4	Expenses				
a	Cost of material consumed	2,808.09	3,807.81	2,998.98	12,770.31
b	Purchases of Stock-in-Trade	-	-	-	-
c	Changes in inventories of finished goods work in progress and stock-in-Trade	162.34	(1,477.39)	(975.91)	(4,740.37)
d	Employee Benefit Expenses	725.41	1,263.96	842.82	3,787.52
e	Finance Costs	997.52	1,813.68	1,138.70	5,240.31
f	Depreciation and Amortisation Expenses	428.55	469.92	482.89	1,825.90
8	Other Expenses	952.07	2,136.96	1,607.94	6,637.50
	Total Expenses	6,073.97	8,014.94	6,095.43	25,521.16
5	Profit before tax (3-4)	99.71	209.15	159.49	513.03
6	Tax Expenses				
	Current Taxes	24.93	(42.36)	31.90	103.79
	Deferred Taxes	-	-	-	(209.31)
	Total tax expenses	24.93	(42.36)	31.90	(105.52)
7	Profit for the period /Year (5-6)	74.78	251.51	127.59	618.55
8	Other Comprehensive income				
	Items that will not be reclassified to profit or loss, net of tax	-	-	-	-
	Items that will be reclassified to profit or loss, net of tax	-	-	-	-
	Total other comprehensive income	-	-	-	-
9	Total comprehensive income (7+8)	74.78	251.51	127.59	618.55
10	Paid up Equity Share Capital	1,658.28	1,650.48	1,650.48	1,650.48
11	Other equity	-	-	-	-
12	Earnings per Share (before Extraordinary Items) (of Rs2/- each)	(not annualised)	(not annualised)	(not annualised)	(annualised)
	(a) Basic	0.09	0.30	0.15	0.75
	(b) Diluted	0.09	0.29	0.15	0.72

1. The above Standalone unaudited Financial Results for the Quarter ended June 30, 2019 have been reviewed and recommended by the Audit Committee and approved by the Board of Directors at their meeting held on 09.08.2019. The Financial results are prepared in accordance with the Indian Accounting standards (IndAS) as prescribed under section 133 of the companies Act, 2013 read with the companies (Indian Accounting Standards) Rules, 2015 (as amended)

2. In line with provisions of Ind AS 108 Operating segments, the Company has primarily two segments "speciality chemicals" and "Pharma" and accordingly considered under reportable segments by the Company.

3. Corresponding numbers of previous period / year have been regrouped, wherever necessary.

Place : Hyderabad

Date : 09.08.2019



For VIVIMED LABS LIMITED

(SANTOSH VARALWAR)
MANAGING DIRECTOR

VIVIMED LABS LIMITED
SEGMENT-WISE STANDALONE FINANCIAL RESULTS

Rs in Lakhs

Particulars	3 Months Ended			FY 19
	30.06.2019	31.03.2019	30.06.2018	31.03.2019
	(Unaudited)	(Audited)	(Unaudited)	(Audited)
1. Segment Revenue (net sales/income from each segment should be disclosed under this head)				
a.Speciality Chemicals Business	2,118.43	659.89	1,769.29	5,651.77
b.Pharma Business	3,792.71	6,316.84	4,429.24	19,045.78
Total	5,911.14	6,976.73	6,198.53	24,697.55
Less, Inter Segment Revenue				
Net sales / Income from Operations	5,911.14	6,976.73	6,198.53	24,697.55
2.Segment Results (Profit) (+) / Loss (-) before tax and interest from each segment				
a.Speciality Chemicals Business	232.25	210.77	411.27	888.47
b.Pharma Business	864.97	1,812.06	886.92	4,864.87
Total	1,097.23	2,022.83	1,298.19	5,753.34
Less: 1.Interest	997.52	1,813.68	1,138.70	5,240.31
2.Other Un-allocable Expenditure				
3.Un-allocable Income				
Total Profit Before Tax	99.71	209.15	159.49	513.03

Segmental capital employed

As certain assets of the company including manufacturing facilities and treasury assets and liabilities are often deployed interchangeability across segments, it is impractical to allocate these assets and liabilities to each segment. Hence, the details for capital employed have not been disclosed in the above table.

Place : Hyderabad

Date : 09.08.2019



For VIVIMED LABS LIMITED

(SANTOSH VARALWAR)
MANAGING DIRECTOR



P C N & ASSOCIATES
CHARTERED ACCOUNTANTS
Plot No. 12, "N Heights"
Ground Floor, Software Layout Unit
Cyberabad, Hyderabad - 500 081.


Tel. : (91-40) 2311 9499
E-mail : pcnassociates@yahoo.com

Independent Auditor's Review Report on the Quarterly Unaudited Consolidated Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

**Review Report to
The Board of Directors
Vivimed Labs Limited**

- 1) We have reviewed the accompanying Statement of unaudited Consolidated Financial Results of **Vivimed Labs Limited** ("the Parent") and its subsidiaries (the Parent and its subsidiaries together referred to as 'the Group'), for the quarter ended June 30, 2019 (the "Statement") attached herewith, being submitted by the Parent pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('the Regulation') read with SEBI Circular No. CIRICFD/CMD1/44/2019 dated March 29, 2019 ('the Circular').
- 2) This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India read with the Circular. Our responsibility is to express a conclusion on the Statement based on our review.
- 3) We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the Circular issued by the Securities and Exchange Board of India under Regulation 33(8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended, to the extent applicable.





P C N & ASSOCIATES

CHARTERED ACCOUNTANTS

Plot No. 12, "N Heights"

Ground Floor, Software Layout Unit
Cyberabad, Hyderabad - 500 081.

Tel. : (91-40) 2311 9499


E-mail : pcnassociates@yahoo.com


4) The Statement includes the results of the following subsidiaries:

- a) Finoso Pharma Pvt Limited
- b) Vivimed Speciality chemicals Pvt Ltd
- c) Vivimed Labs USA, Inc.,
- d) Vivimed Labs Mauritius Limited
- e) Vivimed Holdings Limited
- f) Vivimed Labs Europe Limited
- g) Vivimed Labs UK Limited
- h) Vivimed Labs Spain, S.L.
- i) Union Quimico Farmaceutica S.A.U., Spain
- j) Holliday International Limited, UK
- k) Uquifa Mexico S.A. de C.Y.
- l) Vivimed Labs (Mascarene) Ltd
- m) Soncas Chemicals Ltd
- n) Soneas Research Ltd
- o) UQUIFA India Private Limited

5) Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review reports of other auditors referred to in paragraph 6 (b) above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with recognition and measurement principles laid down in the aforesaid Indian Accounting Standard specified under Section 133 of the Companies Act, 2013, as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Regulation, read with the Circular, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For P C N & Associates
Chartered Accountants
FRN: 016016S


Chandra Babu M
Partner
M.No. 227849



Place: Hyderabad

Date: 09-08-2019

UDIN: 19227849 AAAA FL2415



P C N & ASSOCIATES

CHARTERED ACCOUNTANTS

Plot No. 12, "N Heights"

Ground Floor, Software Layout Unit

Cyberabad, Hyderabad - 500 081.

Tel. : (91-40) 2311 9499


E-mail : pcnassociates@yahoo.com


Independent Auditor's Review Report on the Quarterly Unaudited Standalone Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

**Review Report to
The Board of Directors
Vivimed Labs Limited**

1. We have reviewed the accompanying statement of unaudited Standalone financial results of M/s. Vivimed Labs Limited for the quarter ended 30th June, 2019, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('the Regulation'), read with SEBI Circular No. CIRICFD/CMD1/44/2019 dated March 29,2019 ('the Circular').
2. The preparation of the Statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013, as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, read with the Circular is the responsibility of the Company's management and has been approved by the Board of Directors of the Company. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, *Review of interim financial information performed by the independent auditor of the entity* issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the applicable Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of the Regulation, read with the Circular, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For P C N & Associates
Chartered Accountants
FRN: 016016S


Chandra Baba M
Partner
M.No. 227849



Place: Hyderabad

Date: 09-08-2019

UDIN: 19227849AAAFK3793